Indian AI imaging firm In-Med Prognostics has obtained $2.13 million in funding from Exxora and different angel buyers.
WHAT IT DOES
Established in 2018, the corporate leverages deep studying and machine studying algorithms to generate mind scan analyses to help the evaluation and early detection of neurological issues, together with dementia, Alzheimer’s illness, and Parkinson’s illness.
It presently has three software program choices: NeuroFlo, a neurology workflow platform; NeuroShield, an AI-based app powered by NeuroFlo that gives ethnicity-specific volumetric evaluation report of the mind inside 20 minutes; and VivoShield Sports activities, additionally an AI-powered platform that delivers insights for precision evaluation within the space of sports activities drugs for athlete wellness and optimum efficiency.
In-Med Prognostics has tie-ups with main diagnostics suppliers and hospitals in India, together with Aarthi Scans, Scansworld, Gujarat Scans, Nanavati Hospital, and Kauvery Hospital.
Except for India, it additionally has workplaces in Australia and the US.
WHAT IT’S FOR
In-Med Prognostics will use its new funds to broaden its product portfolio and broaden its attain throughout international markets. Presently, it’s establishing its presence in Africa.
“This funding by Exxora pivots us to develop some cutting-edge options as a part of our innovation funnel within the neurosciences house and ship in each quantity and worth markets,” co-founder Rajesh Purushottam mentioned.
Fellow India-based AI imaging agency qure.ai additionally bagged investments this yr, together with $40 million in a funding spherical led by Novo Holdings and HealthQuad in March, and one other £3.2 million ($3.9 million) from SBRI Healthcare to exhibit using its qXR chest X-ray interpretation expertise to help lung most cancers prognosis.